Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study

ConclusionsLong-term treatment with lasmiditan was associated with significant reductions in migraine-related disability, including both work or school absenteeism and presenteeism. The similarity of responses in completers and those who dropped out suggests that selective attrition does not account for the improvements. Benefits were significant at 3 months and maintained through 12 months.Trial registrationclinicaltrials.govNCT02565186; first posted October 1, 2015.

http://link.springer.com/10.1186/s10194-020-01088-4

Source: The Journal of Headache and Pain - February 23, 2020 Category: Neurology Source Type: research